This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Derma Sciences Reports Third Quarter 2012 Financial Results

“Our 54-person domestic field sales organization is beginning to hit its stride and we are very pleased to report 17% sequential-quarter sales growth in advanced wound care products with the same number of sales reps in both periods. We continue to expect 30% to 40% advanced wound care sales growth in 2013, and as a result our operating business, excluding DSC127 development expenses, is expected to achieve positive cash flow. In addition, as a result of the increase in our higher-margined advanced wound care products, which now account for more than one-third of net sales, our gross margin increased by more than five percentage points to 35.2% in the third quarter versus the prior year.

“As promised, revenue from advanced wound care products other than TCC products grew 36% during the quarter and 30% year-to-date, in line with our expectations for organic growth. We are very pleased that following the integration of MedEfficiency, revenues for TCC products grew 14% in the current quarter over the second quarter. Our TCC products, along with the MEDIHONEY family of dressings, are anchoring our advanced wound care product portfolio. In fact, MEDIHONEY has performed so well, that we will make a $1.0 million milestone payment to Comvita on November 30 th, based on reaching $10.0 million in MEDIHONEY sales.”

Mr. Quilty continued, “Last month we held a positive and constructive meeting with the FDA to discuss our drug candidate DSC127 and we expect to submit a final protocol for Phase 3 development to the FDA by the end of the month. We remain on track to begin studies with DSC127 for the treatment of diabetic foot ulcers by the end of the year.”

Mr. Quilty added, “Our traditional wound care products performed as expected during the quarter, with growth driven by first-aid products, and contributed positive cash flow to support our advanced wound care efforts. While this business will fluctuate from quarter to quarter, we are on track to meet our annual sales growth objective of 2% to 4%.”

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.23 -1.10%
FB $119.32 1.30%
GOOG $709.55 1.20%
TSLA $215.48 1.90%
YHOO $37.19 0.68%


Chart of I:DJI
DOW 17,686.22 +25.51 0.14%
S&P 500 2,050.14 -0.49 -0.02%
NASDAQ 4,710.2950 -6.7990 -0.14%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs